- $932.18m
- $414.86m
- $6.50m
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
Brief: Aktis Oncology Receives U.S. FDA Fast Track Designation For Aky-1189
Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO (updated)
J.P. Morgan initiates coverage of Aktis Oncology with 'overweight' rating
U.S. RESEARCH ROUNDUP-Adobe, Exxon Mobil, Stellar Bancorp
U.S. STOCKS ON THE MOVE-Intel, Gartner, Chipotle
Brief: Akoustis Technologies Files For Chapter 11 Bankruptcy - Court Filing
Brief: Akoustis Technologies Appeals Qorvo Litigation
Brief: Akoustis Technologies - On Nov 21, District Court Entered Amended Final Judgment Against Co In Qorvo Litigation
Akoustis Technologies Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Akoustis Technologies Says District Court Issued Order Denying Qorvo's Motion To Amend Jury's Finding
Brief: Akoustis Technologies Inc On Oct 10, Co Received Notice From Nasdaq That It Is Not In Compliance With Nasdaq Listing Rule 5550(B)(1)
Brief: Akoustis Technologies Appointed Kamran Cheema As The Co’s Permanent Chief Executive Officer
Brief: Akoustis Technologies Says District Court Issued Order On Pre-And Post-Judgment Interest
Brief: Akoustis Technologies On Sept 9, District Court Issued Order Granting In Part & Denying In Part Qorvo's Motion For Attorneys' Fees
Akoustis Technologies Inc expected to post a loss of 11 cents a share - Earnings Preview